MEK1 (Thr386) polyclonal, anti-human, mouse, rat, bovine, dog, chicken, Xenopus
€536.00
In stock
SKU
252556
Protein Family: Enzymes, Protein Kinases
Pathway and Disease: Signal Transduction, Cancers, Cell Growth and Death,Cell Motility, Metabolic Disorders, Cell Communication, Immune System, Endocrine System, Nervous and Sensory Systems, Neurodegenerative Disorders, Development and Behavior
Description:
MEK1 (MAPKK1) catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. MEKI (MAPKK1) activates ERK1 and ERK2 MAP kinases, enzymes which are involved in numerous signal transduction pathways. Defects in MEK1 (MAPKK1) are a cause of cardiofaciocutaneous syndrome (CFC syndrome), also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. The sites on MEK 1 that are phosphorylated by MAP kinase are Thr292 and Thr386.
Alternate Names: MAPKK1, Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK1, ERK activator kinase 1, MAPK/ERK kinase 1, MEK1, MAP2K1, PRKMK2
Application Notes: E: 1:1,000; WB: 1:1,000
Accession No.: Q02750
Antigen: KLH-conjugated synthetic phosphopeptide encompassing a sequence surrounding Thr386 of human MEK1.
Format: Each vial contains 0.1 ml IgG in HEPES pH7.5, 150 mM NaCl, 0.01% BSA and 50% glycerol. Antibody was purified by immunogen affinity chromatography.
Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.
Pathway and Disease: Signal Transduction, Cancers, Cell Growth and Death,Cell Motility, Metabolic Disorders, Cell Communication, Immune System, Endocrine System, Nervous and Sensory Systems, Neurodegenerative Disorders, Development and Behavior
Description:
MEK1 (MAPKK1) catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. MEKI (MAPKK1) activates ERK1 and ERK2 MAP kinases, enzymes which are involved in numerous signal transduction pathways. Defects in MEK1 (MAPKK1) are a cause of cardiofaciocutaneous syndrome (CFC syndrome), also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. The sites on MEK 1 that are phosphorylated by MAP kinase are Thr292 and Thr386.
Alternate Names: MAPKK1, Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK1, ERK activator kinase 1, MAPK/ERK kinase 1, MEK1, MAP2K1, PRKMK2
Application Notes: E: 1:1,000; WB: 1:1,000
Accession No.: Q02750
Antigen: KLH-conjugated synthetic phosphopeptide encompassing a sequence surrounding Thr386 of human MEK1.
Format: Each vial contains 0.1 ml IgG in HEPES pH7.5, 150 mM NaCl, 0.01% BSA and 50% glycerol. Antibody was purified by immunogen affinity chromatography.
Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.
| Is Featured? | No |
|---|
Write Your Own Review